A Study to Assess AFM13 in Patients With Hodgkin Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to determine the safety, tolerability, pharmacokinetics and activity of single cycles of AFM13 in patients with CD30 positive refractory and/or relapsed Hodgkin lymphoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

NCT05883449

Relapsed or Refractory Hodgkin Lymphoma Peripheral T Cell Lymphoma

TERMINATED PHASE2

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

NCT03192202

Lymphoma, T-Cell, Cutaneous

COMPLETED PHASE1/PHASE2

Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

NCT04101331

Peripheral T Cell Lymphoma Transformed Mycosis Fungoides

COMPLETED PHASE2

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT01647971

Non-Hodgkins Lymphoma B-cell Lymphoma Waldenstrom's Macroglobulinemia +4 more

COMPLETED PHASE1/PHASE2

A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

NCT05444322

Mantle Cell Lymphoma Diffuse Large B-cell Lymphoma Follicular Lymphoma

UNKNOWN EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Objectives:

The overall objective of this study is to determine the safety, tolerability, pharmacokinetics and activity of single cycles of AFM13 in patients with CD30 positive refractory and/or relapsed Hodgkin lymphoma.

Objectives:

1. To determine the safety and tolerability of increasing doses of single cycles of AFM13 monotherapy.
2. To determine the OBD (Optimal Biological Dose) or MTD (Maximum Tolerated Dose) of AFM13; whichever is reached first.
3. To define the pharmacokinetic profile of AFM13.
4. To analyse immunological markers e.g. ADCC (Antibody dependent cell mediated cytotoxicity), NK (Natural killer) cell activity, complement activation and depletion, and cytokine release.
5. To assess the immunogenicity of AFM13.
6. To assess the activity of AFM13.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hodgkin Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AFM13

IV (intravenous) infusion, dose escalation

Group Type EXPERIMENTAL

AFM 13

Intervention Type DRUG

Cohort escalation then expansion phase design. Starting dose 0.01 mg/kg. 4 weekly drug administrations.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AFM 13

Cohort escalation then expansion phase design. Starting dose 0.01 mg/kg. 4 weekly drug administrations.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Histological diagnosis of relapsed or refractory Hodgkin lymphoma expressing the CD30 antigen.
2. Age ≥18 years.
3. Both genders.
4. Patients who have relapsed or are refractory after at least two prior potentially curative therapies including autologous stem cell transplantation (ASCT). Patients with a progressive disease after the first-line therapy who are ineligible for, or refused to receive high dose chemotherapy and/or ASCT for the second-line therapy, or any other established curative therapy, are also eligible.
5. Completed radiotherapy, chemotherapy, and/or treatment with other investigational agents at least 3 weeks prior to study entry.
6. Patients who received ASCT should have fully recovered prior to study entry.
7. Eastern Cooperative Oncology Group (ECOG) status of ≤2.
8. Laboratory data:

1. Platelet count \>75,000/mm3;
2. Hemoglobin \>9.0 g/dL (may be maintained by transfusion);
3. Absolute neutrophil count \>1500/mm3;
4. ALT/AST (Alanine aminotransferase/Aspartate aminotransferase)\<2.5 times the upper limit of normal (ULN);
5. Total bilirubin \<1.5 times ULN;
6. Creatinine \<1.5 mg/dL.
9. Female patients of childbearing potential who are not surgically sterile or postmenopausal and male patients who are not surgically sterile must agree to use medically effective contraception during the treatment period and up to 60 days after the last AFM13 administration. The patient must agree to sign his or her consent on this particular inclusion criterion.
10. Ability to give written, informed consent prior to any study-specific screening procedures, with the understanding that the consent may be withdrawn by the patient at any time without prejudice.
11. Be willing and able to comply with the study protocol for the duration of the study.

Exclusion Criteria

1. Any significant diseases (other than HL (Hodgkin Lymphoma)) or clinically significant findings, including psychiatric and behavioral problems, medical history and/or physical examination findings that would preclude the patient from participating in the study.
2. History or clinical evidence of central nervous system (CNS) HL.
3. Allogeneic SCT.
4. Major surgery within 4 weeks prior to study entry.
5. Known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation.
6. Known history of another primary malignancy that has not been in remission for at least 5 years. Non-concurrent non-melanoma skin cancer and cervical carcinoma in situ or squamous intraepithelial lesions (e.g., cervical intraepithelial neoplasia \[CIN\] or prostatic intraepithelial/intraductal neoplasia \[PIN\]) are allowed.
7. Any active viral, bacterial, or systemic fungal infection within 4 weeks prior to study entry.
8. Known to be positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg), or hepatitis C virus (HCV).
9. History of significant chronic or recurrent infections requiring treatment.
10. Receiving systemic steroid prednisone or equivalent during the 3 weeks immediately preceding enrollment.
11. Pregnant or breast-feeding.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No